Orsight Pharma · raw details

Neovascular Age-Related Macular Degeneration Drug Treatment · Nazareth, Israel · Founded 2023

active Pre-Seed ← back to profile

Highlights

IIA supported (ever)

About

Neovascular Age-Related Macular Degeneration Drug Treatment

Orsight Pharma develops a breakthrough small molecule treatment designed to preserve vision and prevent blindness through a novel VEGF-independent mechanism. This drug offers a ray of hope, especially for those who have not seen satisfactory results with existing treatments. The company's product not only stands to benefit patients unresponsive to current therapies but also has the potential to enhance visual outcomes when used in combination with them.

Identity

NameOrsight Pharma
Slugorsight-pharma
Type / kindstartup
Source _idOLKoxnDuboLpl7sJ3vRBtwGpWN2pjKIA76RjOH4eH30tb5RRyERW03

Status

Statusactive
Last update2026-05-17

Location

HQ countryIsrael
HQ country codeIL
HQ region/districtNorth District
HQ cityNazareth
HQ addressNazareth, Israel

Web & social

LinkedInhttps://www.linkedin.com/company/101609804

Classifications

Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Business models
B2C

Funding

Total raised$2.1M
Current stagePre-Seed

Raw source document

Show full JSON (0 KB) 
{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}